DNA Damage Response Drugs Market Overview by Recent Opportunities, Growth Size, Regional Analysis and Forecasts to 2030

Our healthcare experts have found DNA damage response drugs industry to be one of the most rapidly evolving markets. The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.

The market is favored by the developments in the field of oncology research for discovering underlying molecular mechanisms of cancerous cells for the development of novel therapeutics. Moreover, the growing cases of advanced cancer worldwide has significantly escalated the need for developing DNA damage response drugs for solving cancer unmet needs. These drugs have unprecedented potential in terms of offering a selective and efficient tolerated treatment approach for improving cancer survival rates.

Market Segmentation

• Commercialized Drugs – Lynparza, Talzenna, Zejula, and Rubraca

• Pipeline Analysis (by Mechanism of Action)- PARP Inhibitor, WEE1 Kinase Inhibitor, ATR Kinase Inhibitor, Aurora B Inhibitor, and DNA-PK Inhibitor, and Others

• Application – Ovarian Cancer, Breast Cancer, Pancreatic Cancer, and Prostate Cancer

Regional Segmentation

• North America – U.S., Canada

• Europe – Germany, France, U.K., Italy, Spain, Switzerland, and Rest-of-Europe

• Asia-Pacific – China, Japan, India, Australia, and Rest-of-Asia-Pacific (RoAPAC)

• Latin America – Brazil, and Rest-of-the-Latin America

• Rest-of-the-World

Growth Drivers

• Rising Global Prevalence of Cancer

• Favourable Regulatory Environment

• Increasing Oncology R&D Expenditure

• Increase in Adoption of Precision Medicine in Cancer Treatment

Market Challenges

• High Cost Hindering the Adoption Rate

• Unfavorable Reimbursement Scenario

• Safety Concerns Pertaining to Severe Adverse Effects

Market Opportunities

• Massive Scope in Emerging Regions

Key Companies Profiled

AbbVie Inc., AstraZeneca plc, Bayer AG, BeiGene Ltd., Clovis Oncology, Debiopharm International SA, Eli Lilly & Company, GlaxoSmithKline plc, Merck KGaA, NMS Group S.p.A, Onxeo SA, Pfizer Inc., Repare Therapeutics, Sierra Oncology, Inc., and Zentalis Pharmaceuticals, LLC

Request a Sample - https://bisresearch.com/requestsample?id=953&type=download

Comments

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Clinical Decision Support Systems (CDSS) Market registering a CAGR of 6.70% during the forecast period 2021-2030

The global market for clinical decision support systems (CDSS) registered the market value of $1,918.8 million in 2020 and is expected to reach $3,739.2 million by 2030, registering at a CAGR of 6.70% during the forecast period 2020-2030. The clinical decision support systems of the future are expected to be developed to leverage data to make observations which are not interpretable by humans. Healthcare IT systems in the future are expected to leverage cutting-edge technology as an enabler to make clinical care more streamlined and accurate. The technology is still in its nascent stage. One of the strong points of this technology is that it improves with time. Continuous input from clinicians, patients, and other stakeholders will be essential for correctly implementing the technology to enhance meaningful uses, reduce costs, and improve treatment outcomes. Key USPs of the Report Following are some of the key contents of the report: • Industry Analysis ...

Hyperspectral Imaging Market Projections , Upcoming Trends Focus on Long-Term Impact of Covid-19 and Forecast By 2027

The global hyperspectral imaging market was estimated to be at $791.2 million in 2021, which is expected to grow with a CAGR of 13.17% and reach $1,640.3 million by 2027.The growth in the global hyperspectral imaging market is expected to be primarily driven by increased awareness of the technology in different sectors such as agriculture, healthcare, and mining. The hyperspectral imaging technology has great potential, and the market is anticipated to grow during the forecast period owing to the widespread applications of HSI, increasing investments for RD activities, increasing demand from military and defense sectors, increased food safety concerns, and increasing awareness regarding early diagnosis of diseases. COVID-19 Impact and Post-COVID-19 Scenario The COVID-19 pandemic had a debilitating impact on the global ecosystem. The pandemic led to a shutdown of production facilities, which do not come under essential goods, which led to a negative impact on se...

Market Research Reports

Search This Blog